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Background-—Thrombocytopenia is associated with increased mortality in the general population, but few data exist in patients
with atrial fibrillation (AF) taking oral anticoagulants. We investigated factor determinants of thrombocytopenia in a large cohort of
patients affected by AF and its association with total mortality.
Methods and Results-—Multicenter prospective cohort study, including 5215 patients with AF from the START (Survey on
Anticoagulated Patients Register) registry, 3877 (74.3%) and 1338 (25.7%) on vitamin K or non–vitamin K antagonist oral
anticoagulants, respectively. Thrombocytopenia was defined by a platelet count <1509109/L. Determinants of thrombocytopenia
were investigated, and all-cause mortality was the primary survival end point of the study. Thrombocytopenia was present in 592
patients (11.4%). At multivariable logistic regression analysis, chronic kidney disease (odds ratio [OR], 1.257; P=0.030), active
cancer (OR, 2.065; P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of diuretics (OR, 1.234; P=0.046) were positively
associated with thrombocytopenia, whereas female sex (OR, 0.387; P<0.001) and the use of calcium channel blockers (OR, 0.787;
P=0.032) were negatively associated. During a median follow-up of 19.2 months (9942 patient-years), 391 deaths occurred (rate,
3.93%/year). Mortality rate increased from 3.8%/year to 9.9%/year in patients with normal platelet count and in those with
moderate-severe thrombocytopenia, respectively (log-rank test, P=0.009). The association between moderate-severe thrombo-
cytopenia and mortality persisted after adjustment for CHA2DS2 VASc score (hazard ratio, 2.431; 95% CI, 1.254–4.713; P=0.009),
but not in the fully adjusted multivariable Cox regression analysis model.
Conclusions-—Thrombocytopenia is common in patients with AF. Despite an increased incidence of mortality, thrombocytopenia
was not associated with mortality at multivariable analysis. Thrombocytopenia may reflect the presence of comorbidities
associated with poor survival in AF. ( J Am Heart Assoc. 2019;8:e012596. DOI: 10.1161/JAHA.119.012596.)
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T he most common causes of thrombocytopenia in adultsinclude acute and chronic infectious diseases, liver
cirrhosis, cancer, and use of drugs like heparin, chemother-
apies, antibiotics, and antidiabetic medications.1 In addition,
platelet count may be reduced in patients with myelofibrosis
or hematologic diseases.
Thrombocytopenia is usually defined as a platelet count
<1509109/L, and in the general population, it is associated
with an increased risk of mortality.2 Furthermore, the
presence of a low platelet count was associated with worse
short- and long-term outcomes in patients with acute
coronary syndrome or cancer.3,4
The management of patients with thrombocytopenia
requiring oral anticoagulation, such as those with venous
thromboembolism or atrial fibrillation (AF), is particularly
challenging for the potential risk of bleeding.3,5 Indeed,
anticoagulation is generally contraindicated if platelet count is
<509109/L,6 and patients with platelet count <1009109/L
were excluded from recent clinical trials with non–vitamin K
antagonist (VKA) oral anticoagulants (NOACs).7–10 Prevalence
and determinants of thrombocytopenia in AF patients are still
unclear. In 2 recent studies, the prevalence of thrombocy-
topenia was highly variable, as it ranged from 6% to 24%.4,5
Furthermore, follow-up data about the relationship between
thrombocytopenia and mortality in patients with AF were not
reported.
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On the basis of this, the aim of the present study was to
assess prevalence and determinants of thrombocytopenia and
its relationship with mortality in a large population of the
multicenter cohort START (Survey on Anticoagulated Patients
Register) registry.
Methods
Study Population
The authors declare that all supporting data are available
within the article. Details of the START registry have been
previously described.11 Briefly, the START registry is an
observational, multicenter, ongoing cohort study that includes
patients (aged ≥18 years) who start anticoagulation therapy
(ClinicalTrials.gov NCT02219984). The study protocol was
accepted by the Institutional Review Board of each partici-
pating center, and informed consent was obtained from
patients at enrollment. The present analysis is limited to
patients with nonvalvular AF starting oral anticoagulants,
either VKAs (warfarin or acenocoumarol) or NOACs. Patients
treated with low-molecular-weight heparin were excluded.
Patients with a life expectancy <6 months, not residents in
the participant region, or planning on leaving in the next
6 months were not included in the registry, as well as patients
already enrolled in phase 2 or 3 clinical studies. Patients
enrolled in other observational or phase 4 studies were
considered eligible for the study.
Thrombocytopenia was defined by a platelet count
<1509109/L.12 Primary end point of the study was the
occurrence of all-cause mortality. Data on death were obtained
from relatives of patients or from general practitioners.
CHA2DS2 VASc [congestive heart failure (1 point), hyperten-
sion (1 point), age ≥75 years (2 points), diabetes (1 point), prior
stroke (2 points), age 65–74 years (1 point), female sex (1
point), and vascular disease (1 point)] and HAS BLED
(hypertension i.e. uncontrolled, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile international
normalized ratio, age >65 years, drugs/alcohol concomitantly)
scores were also calculated. In the HAS BLED, the “L” of labile
international normalized ratio was scored 0.
Statistical Analysis
Data are expressed as mean and SD or median and interquar-
tile range, depending on variable distribution. Group compar-
isons were performed by unpaired Student t test. Proportions
and categorical variables were tested by the v2 test.
We divided patients’ cohort according to the presence of
thrombocytopenia (ie, platelet count <1509109/L) and
performed a descriptive analysis of characteristics of patients
with and without low platelet count.
Multivariable logistic regression analysis was used to
investigate factors associated with thrombocytopenia and to
estimate the adjusted odds ratio (OR) of each variable.
Variables were categorized or dichotomized for the multi-
variable model, which included the following covariates:
persistent/permanent AF (versus paroxysmal AF), female
sex, aged ≥75 years, obesity (body mass index ≥30 kg/m2),
chronic kidney disease (creatinine clearance <60 mL/min),
active cancer, diabetes mellitus, previous cerebrovascular
events, previous cardiovascular disease, heart failure, periph-
eral artery disease, pulmonary disease, liver cirrhosis, smok-
ing, NOACs use (versus VKAs), antiplatelet drugs, lipid-
lowering drugs, antiarrhythmic drugs, angiotensin-converting
enzyme inhibitors, b blockers, calcium channel blockers,
diuretics, nitrate, angiotensin receptor blockers, digoxin,
proton pump inhibitors, and xanthine oxidase inhibitors.
Survival analysis was performed to investigate the rela-
tionship between thrombocytopenia and all-cause mortality.
For this analysis, patients were divided in 3 groups: normal
(>1509109/L), mildly reduced (150–1009109/L), and mod-
erately severely reduced (<1009109/L) platelet count.
The cumulative incidence of all-cause mortality was
estimated using a Kaplan-Meier product-limit estimator, and
survival curves were formally compared using the log-rank
test. Univariate and multivariate stepwise Cox proportional
hazards regression analysis was used to calculate the
adjusted relative hazard ratios (HRs) of death by each clinical
variable. Three models of survival analysis were built: model A,
adjusted for age and sex; model B, adjusted for CHA2DS2
VASc score; and model C, fully adjusted.
Clinical Perspective
What Is New?
• Thrombocytopenia is common in patients experiencing atrial
fibrillation and taking oral anticoagulants.
• Platelet count was lower in men than women and decreased
by aging, and the presence of chronic kidney disease, active
cancer, and liver cirrhosis was associated with thrombocy-
topenia.
• We observed a significant association between moderate-
severe thrombocytopenia and mortality, which persisted
after adjustment for CHA2DS2 VASc score.
What Are the Clinical Implications?
• Thrombocytopenia may identify a subgroup of patients with
atrial fibrillation at higher risk of mortality.
• When thrombocytopenia is detected, the presence of
comorbidities potentially affecting survival should be
investigated.
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All tests were 2 tailed, and P<0.05 was considered
statistically significant. Analyses were performed using com-
puter software (IBM SPSS 23 Inc).
Results
The cohort was composed of 5236 patients with AF; 4
patients had missing data, and 17 patients taking low-
molecular-weight heparin were excluded. Thus, the analysis
was performed in 5215 patients. Of these patients, 3877
(74.3%) were taking VKAs, and 1338 (25.7%) NOACs: 469
taking dabigatran, 478 taking apixaban, 379 taking rivarox-
aban, and 12 taking edoxaban.
Characteristics of patients are reported in Table 1. The
mean age was 75.09.6 years, and 2368 (45.4%) were
women. Overall, thrombocytopenia was present in 592
patients (11.4%) (Table 1). Of these patients, 10.4% had mild
and 0.96% had moderate-severe thrombocytopenia. Patients
with thrombocytopenia were older; they were more likely to
have persistent/permanent AF, active cancer, and liver
cirrhosis; and more of them were treated with calcium
channel blockers, nitrate, diuretics, and xanthine oxidase
inhibitors. A trend for higher use of lipid-lowering drugs and
proton pump inhibitors and diabetes mellitus was also found
(Table 1). Among antiarrhythmic drugs, 147 were treated with
propafenone, 258 were treated with flecainide, 674 were
treated with amiodarone, and 229 were treated with other
drugs (dronedarone/unknown).
The CHA2DS2 VASc score was similar between the 2
groups, whereas the HAS BLED score was significantly higher
in patients with thrombocytopenia (Table 1).
Women were less likely to have thrombocytopenia com-
pared with men (Table 1). Thus, median platelet count was
significantly lower in men than women, independently from
aging (Table 2). In particular, in male but not female patients,
a significant decrease in platelet count was found according
to age group (Table 2).
At multivariable logistic regression analysis, chronic kidney
disease (OR, 1.257; P=0.030), active cancer (OR, 2.065;
P=0.001), liver cirrhosis (OR, 7.635; P<0.001), and the use of
diuretics (OR, 1.234; P=0.046) were positively associated with
thrombocytopenia, whereas female sex (OR, 0.387; P<0.001)
and calcium channel blockers (OR, 0.787; P=0.032) were
negatively associated (Table 3).
Survival Analysis
Median follow-up was 19.2 (interquartile range, 8.8–35.4)
months, yielding 9942 patient-years of observation; 391
deaths were registered with an annual incidence rate of 3.93%
(95% CI, 3.6%–4.3%). Incidence of mortality increased from
3.8%/year in patients with normal platelet count to 9.9%/year
in those with moderate-severe thrombocytopenia (Table 4).
Kaplan-Meier curves showed a significant decrease of
survival across the 3 groups of thrombocytopenia (log-rank
test, P=0.009; Figure). Univariate Cox regression analysis
showed that moderate-severe, but not mild, thrombocytope-
nia was associated with mortality (Table 4). Among antiar-
rhythmic drugs, we found that propafenone (univariate HR,
0.339; 95% CI, 0.126–0.908; P=0.031) and flecainide (n=258;
univariate HR, 0.370; 95% CI, 0.183–0.747; P=0.006), but not
amiodarone (n=674; univariate HR, 0.865; 95% CI, 0.640–
1.169; P=0.344) or other antiarrhythmic drugs (n=229
dronedarone/unknown; univariate HR, 0.692; 95% CI,
0.412–1.162; P=0.164), were associated with mortality.
However, given the low number of deaths in each group (4
in the propafenone group, 8 in the flecainide group, 49 in the
amiodarone group, and 15 in the other group), antiarrhythmic
drugs were grouped for multivariable analysis.
The association between moderate-severe thrombocytope-
nia and mortality persisted after adjustment for age and sex
(Table 5,model A) andCHA2DS2VASc score (Table 5,model B).
However, it was no longer significant at fully adjusted
multivariable Cox regression analysis (Table 5, model C): HR,
1.147 (95%CI, 0.840–1.566; P=0.390) for platelet count 150 to
1009109/L; and HR, 1.712 (95% CI, 0.873–3.3354; P=0.117)
for platelet count <1009109/L versus normal platelet count.
All significant predictors of mortality are reported in Table 5.
Thrombocytopenia and Bleeding
During follow-up, 133 major bleeding events were reported.
Univariate Cox regression analysis found that moderate-
severe thrombocytopenia resulted in a significant association
with major bleeding (HR, 3.699; 95% CI, 1.170–11.692;
P=0.026). This association was not evident for mild throm-
bocytopenia (HR, 1.218; 95% CI, 0.700–2.118; P=0.486).
Discussion
The study shows a relatively high prevalence of thrombocy-
topenia in AF patients on treatment with oral anticoagulants.
The incidence of mortality increased with the severity of
thrombocytopenia and persisted after adjustment for
CHA2DS2 VASc score.
The present study reports a prevalence of thrombocytope-
nia of 11.4%, which is in between the prevalence reported in
previous studies.4,5 For the study that reported a prevalence of
5.7% of white patients, it is possible that the difference in age
of the population could account for the different results; thus,
the mean age of the cohort of Yadav et al. was lower than that
of our study (mean, 65 versus 75 years, respectively).4
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Table 1. Characteristics of Patients With AF, According to the Presence of Thrombocytopenia
Characteristics All Cohort (n=5215) Normal Platelet Count (n=4623) Thrombocytopenia (n=592) P Value
Persistent/permanent AF 3282 (62.9) 2883 (62.4) 399 (67.4) 0.017
Women 2368 (45.4) 2207 (47.7) 161 (27.2) <0.001
Age, y 75.09.6 74.99.7 75.69.2 0.115
Aged ≥75 y 3051 (58.5) 2692 (58.2) 359 (60.6) 0.268
BMI, kg/m2 26.84.7 26.84.7 27.04.6 0.505
Obesity (BMI ≥30 kg/m2) 1101 (21.1) 974 (21.1) 127 (21.5) 0.831
Creatinine clearance, mL/min 66.828.3 66.928.2 65.929.0 0.420
CKD (creatinine clearance <60 mL/min) 2357 (45.2) 2075 (44.9) 282 (47.6) 0.219
Active cancer 134 (2.6) 104 (2.2) 30 (5.1) <0.001
Hypertension 4182 (80.2) 3694 (79.9) 488 (82.4) 0.155
Diabetes mellitus 1048 (20.1) 911 (19.7) 137 (23.1) 0.056
Previous cerebrovascular events 857 (16.4) 765 (16.5) 92 (15.5) 0.556
Previous cardiovascular disease 966 (18.5) 817 (17.7) 149 (25.2) <0.001
Heart failure 808 (15.5) 706 (15.3) 102 (17.2) 0.227
Peripheral artery disease 332 (6.4) 289 (6.3) 43 (7.3) 0.326
Pulmonary disease 655 (12.6) 580 (12.5) 75 (12.7) 0.947
Liver cirrhosis 27 (0.5) 13 (0.3) 14 (2.4) <0.001
Smoking 688 (13.2) 609 (13.2) 79 (13.3) 0.897
CHA2DS2 VASc score 3.61.5 3.61.5 3.61.4 0.795
HAS BLED score 1.270.73 1.260.73 1.350.73 0.010
Anticoagulant drugs 0.294
VKAs 3877 (74.3) 3426 (74.1) 451 (76.2)
NOACs 1338 (25.7) 1197 (25.9) 141 (23.8)
Dabigatran 469 (9.0) 416 (9.0) 53 (9.0)
Apixaban 478 (9.2) 424 (9.2) 54 (9.1)
Rivaroxaban 379 (7.3) 345 (7.5) 34 (5.7)
Edoxaban 12 (0.2) 12 (0.3) 0 (0.0)
Antiplatelet drugs 646 (12.4) 560 (12.1) 86 (14.5) 0.098
Aspirin 507 (9.7) 444 (9.6) 63 (10.6) 0.418
Others 205 (3.9) 175 (3.8) 30 (5.1) 0.143
Lipid-lowering drugs 1803 (34.6) 1580 (34.2) 223 (37.7) 0.098
Antiarrhythmic drugs 1308 (25.1) 1162 (25.1) 146 (24.7) 0.840
ACE inhibitors 1501 (28.8) 1318 (28.5) 183 (30.9) 0.228
b Blockers 2745 (52.6) 2421 (52.4) 324 (54.7) 0.294
Calcium channel blockers 1197 (23.0) 1075 (23.3) 122 (20.6) 0.161
Diuretics 1880 (36.0) 1634 (35.3) 246 (41.6) 0.004
Nitrate 260 (5.0) 219 (4.7) 41 (6.9) 0.027
Angiotensin receptor blockers 1191 (22.8) 1051 (22.7) 140 (23.6) 0.640
Digoxin 480 (9.2) 427 (9.2) 53 (9.0) 0.880
Proton pump inhibitors 2384 (45.7) 2093 (45.3) 291 (49.2) 0.080
Xanthine oxidase inhibitors (allopurinol and febuxostat) 386 (7.4) 329 (7.1) 57 (9.6) 0.037
Data are given as number (percentage) or meanSD. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; NOAC, non-
VKA oral anticoagulant; VKA, vitamin K antagonist.
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Conversely, a significantly higher prevalence of thrombocy-
topenia of 24.2% has been reported in the Korean population,5
despite a significantly lower prevalence of comorbidities,
such as hypertension, chronic kidney disease, and previous
cerebrovascular events, compared with the present cohort.
Another large nationwide study, including 8478 middle-aged
participants without cardiovascular risk factors, reported a
prevalence of thrombocytopenia of 16.5%.13
We found that chronic kidney disease, active cancer, and
liver cirrhosis, which are frequent features of patients with
Table 2. Median (Interquartile Range) Platelet Count, According to Age and Sex Groups
Variable Men Women P Value (Between Sex Groups)
Age below median (≤75 y) 206 (173–246) 229 (195–276) <0.001
Age above median (>75 y) 196 (163–240) 225 (188–272) <0.001
P value (between age groups) <0.001 0.201 . . .
Platelet count is given as number9109/L.
Table 3. Multivariable Logistic Regression Analysis of Factors Associated With Thrombocytopenia (Platelet Count <1509109/L)
Variable Odds Ratio
95% CI
P ValueLower Upper
Persistent/permanent AF (vs paroxysmal) 1.156 0.956 1.398 0.135
Female sex 0.387 0.316 0.475 <0.001
Aged ≥75 y 1.077 0.879 1.319 0.476
Obesity (BMI ≥30 kg/m2) 1.090 0.869 1.368 0.456
CKD (creatinine clearance <60 mL/min) 1.257 1.022 1.547 0.030
Active cancer 2.065 1.341 3.177 0.001
Diabetes mellitus 1.080 0.868 1.344 0.492
Previous cerebrovascular events 0.930 0.728 1.187 0.559
Previous cardiovascular disease 1.235 0.965 1.580 0.093
Heart failure 0.924 0.714 1.196 0.550
Peripheral artery disease 0.994 0.703 1.407 0.975
Pulmonary disease 0.864 0.658 1.136 0.295
Liver cirrhosis 7.635 3.458 16.854 <0.001
Smoking 0.829 0.638 1.078 0.162
NOAC use (vs VKAs) 0.897 0.728 1.106 0.309
Antiplatelet drugs 0.934 0.710 1.229 0.626
Lipid-lowering drugs 1.014 0.825 1.248 0.892
Antiarrhythmic drugs 1.035 0.840 1.275 0.747
ACE inhibitors 1.056 0.860 1.298 0.601
b Blockers 1.023 0.850 1.231 0.808
Calcium channel blockers 0.787 0.632 0.979 0.032
Diuretics 1.234 1.004 1.517 0.046
Nitrate 1.191 0.819 1.732 0.359
Angiotensin receptor blockers 1.090 0.873 1.361 0.446
Digoxin 1.022 0.745 1.403 0.893
Proton pump inhibitors 1.057 0.877 1.274 0.562
Xanthine oxidase inhibitors 1.076 0.788 1.468 0.645
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; NOAC, non-VKA oral anticoagulant; VKA, vitamin K antagonist.
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AF,14 were significantly associated with thrombocytopenia;
this is in accordance with previous reports in different clinical
settings.15 In addition, we found a sex-based difference in
platelet count, with women having mean higher platelet count
than men. This difference was evident both in younger (aged
≤75 years) and elderly (aged >75 years) patients. This finding
is in keeping with a previous study on a large sample of the
Italian general population,16 showing higher platelet count in
women than men. In the same study, a decrease in platelet
count by aging was present both in men and women, whereas
Table 4. Annual Incidence Rates of Mortality and Univariate HR, According to Thrombocytopenia Groups
Variable
No. of Deaths/No. of
Patients
Annual Incidence
Rate (95% CI) P Value
Univariate HR
(95% CI) P Value
Normal platelet
count (>1509109/L)
334/4623 3.8 (3.4–4.2) Reference Reference Reference
Mild thrombocytopenia (150–1009109/L) 48/542 4.6 (3.4–6.1) 0.230 1.201 (0.888–1.626) 0.235
Moderate-severe
thrombocytopenia (<1009109/L)
9/50 9.9 (4.5–18.8) 0.003*
0.029†
2.558 (1.320–4.961) 0.005
HR indicates hazard ratio.
*vs normal platelet count.
†vs mild thrombocytopenia.
Figure. Kaplan-Meier curves for risk of mortality, according to the presence of thrombocytopenia.
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we found a decrease of platelet count according to age in men
but not in women.
A mortality rate of 3.93%/year was registered in the present
study, which is substantially in line with previous studies
reporting an incidence of mortality ranging from 2.19%17 to
5.15%.18–20 At survival analysis, we found a progressive
increase of mortality rate from 3.8%/year in patients with
normal platelet count to 4.6% and 9.9% in patients withmild and
moderate-severe thrombocytopenia, respectively. This associ-
ation persisted after adjustment for CHA2DS2 VASc score but
was lost at fully adjusted multivariable hazard Cox regression
analysis. This suggests that some risk factors not currently
used for thromboembolic risk stratification, such as chronic
liver and kidney disease or active cancer, may be associated
with thrombocytopenia. These factors should be evaluated in
patients presenting with thrombocytopenia.
Thrombocytopenia has also been proposed as a risk factor for
mortality in other clinical cardiovascular settings, such as patients
experiencing an acute ischemic stroke,21 a myocardial infarc-
tion,22 or undergoing percutaneous coronary intervention.23
However, mechanisms underlying this association have not
been explored. Beyond platelet count, an important factor to
be considered is platelet function, which may be increased by
aging and cardiovascular risk factors.24 Thus, in a previous
study, patients with AF presenting with an increased urinary
excretion of thromboxane B2, a marker of systemic platelet
activation, experienced a higher rate of cardiovascular events,
independently from platelet count.25
Another interesting finding of the study is the inverse
association between antiarrhythmic drugs and mortality. In
particular, univariate analysis showed that propafenone and
flecainide, but not amiodarone, were associated with a lower
mortality rate. However, the low number of deaths in each
group of antiarrhythmic users did not allow us to explore the
association between mortality and single drugs. The associ-
ation between antiarrhythmic drugs and relevant clinical
outcomes, such as thromboembolism, heart failure, ischemic
heart disease, and cardiovascular mortality, needs further
research, mostly considering the potential adverse effects
related to the use of these drugs.26,27
Table 5. Cox Proportional Hazards Regression Analysis of Factors Associated With All-Cause Mortality
Variable HR
95% Confidence Interval
P ValueLower Upper
Model A (adjusted for age and sex)
Mild thrombocytopenia 1.169 0.859 1.591 0.320
Moderate-severe thrombocytopenia 2.232 1.147 4.342 0.018
Sex 0.841 0.686 1.032 0.097
Age 1.134 1.116 1.152 <0.001
Model B (adjusted for CHA2DS2 VASc score)
Mild thrombocytopenia 1.259 0.930 1.704 0.136
Moderate-severe thrombocytopenia 2.431 1.254 4.713 0.009
CHA2DS2 VASc score 1.342 1.257 1.433 <0.001
Model C (stepwise fully adjusted)
Aged ≥75 y 2.339 1.730 3.163 <0.001
Chronic kidney disease (Cr Cl <60 mL/min) 2.372 1.854 3.035 <0.001
Active cancer 2.855 1.869 4.360 <0.001
Diabetes mellitus 1.315 1.035 1.671 0.025
Heart failure 1.382 1.072 1.781 0.013
Pulmonary disease 1.513 1.180 1.941 0.001
Previous cardiovascular disease 1.351 1.047 1.744 0.021
Peripheral artery disease 1.845 1.345 2.531 <0.001
Antiarrhythmic drugs 0.764 0.593 0.984 0.037
Lipid-lowering drugs 0.608 0.477 0.774 <0.001
Diuretics 1.521 1.222 1.894 <0.001
Angiotensin receptor blockers 0.769 0.598 0.989 0.041
Cr Cl indicates creatinine clearance.
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The studys has implications and limitations. The presence
of thrombocytopenia in AF should be regarded as a marker of
coexistence of comorbidities associated with poor survival.
The reasons for men having less platelet count with a decline
according to age should be further investigated. Another
limitation of the study is the lack of information on the quality
of anticoagulation in patients treated with VKAs. Finally, data
reflect a cohort representative of the Italian population and
cannot be transferred to another population. Furthermore, to
better understand the role of thrombocytopenia in patients
with AF taking oral anticoagulants, the association between
thrombocytopenia and other end points, such as cardiovas-
cular events and bleeding, should be further explored.
In conclusion, thrombocytopenia is frequent in patients with
AF receiving treatment with oral anticoagulants. Despite an
increased risk of mortality, thrombocytopenia may not repre-
sent per se a risk factor for mortality but may rather mirror the
presence of comorbidities associated with poor survival.
Appendix
START2 Registry Investigators
Sophie Testa, Oriana Paoletti, UO Laboratorio Analisi, Centro
Emostasi e Trombosi A O Istituti Ospitalieri di Cremona,
Cremona; Benilde Cosmi, Giuliana Guazzaloca, Ludovica Migli-
accio, UO di Angiologia e Malattie Coagulazione, AOU S Orsola-
Malpighi, Bologna, Bologna; Daniela Poli, Rossella Marcucci,
Niccolo Maggini, SOD Malattie Aterotrombotiche, Azienda
Ospedaliero Universitaria-Careggi, Firenze; Vittorio Pengo,
Dipartimento di Scienze Cardio-Toraco-Vascolari, Centro Trom-
bosi, AOU Padova, Padova; Anna Falanga, Teresa Lerede, USC
SIMT, Centro Emostasi e Trombosi, Ospedale Papa Giovanni
XXIII, Bergamo; Lucia Ruocco, UO Analisi Chimico-Cliniche,
Azienda Ospedaliero Universitaria Pisana, Pisa; Giuliana Mar-
tini, Centro Emostasi, Spedali Civili Di Brescia, Brescia; Simona
Pedrini, Federica Bertola, Servizio di Laboratorio, Istituto
Ospedaliero Fondazione Poliambulanza Brescia; Lucilla Mas-
ciocco, Pasquale Saracino, Angelo Benvenuto, UOC Medicina
Interna, Centro Controllo Coagulazione, Presidio Ospedaliero
Lastaria, Lucera (Foggia); Claudio Vasselli, Laboratorio Patolo-
gia Clinica, Policlinico Casilino, Roma; Francesco Violi,
Pasquale Pignatelli, Daniele Pastori, Centro Trombosi, Clinica
Medica Policlinico Umberto I, Universita la Sapienza Roma;
Elvira Grandone, Donatella Colaizzo, Centro Trombosi Casa del
Sollievo e della Sofferenza, S Giovanni Rotondo (Foggia); Marco
Marzolo, UOC Medicina Interna, Ospedale di Rovigo; Mauro
Pinelli, Daniela Mastroiacovo, UOSD Angiologia e Diagnostica
Vascolare, Ospedale SS Filippo e Nicola, Avezzano (L’Aquila);
Walter Ageno, Giovanna Colombo, UO Medicina I, Ospedale di
Circolo, Varese; Eugenio Bucherini, SS Medicina Vascolare-
Angiologia, Ambulatorio Anticoagulanti, Ospedale Civile di
Faenza, Faenza (Ravenna); Domizio Serra, Centro Trombosi,
Ospedale Evangelico Internazionale, Genova; Andrea Toma,
Pietro Barbera, UOC di Patologia Clinica, Ambulatorio Terapia
Anticoagulante Orale, OC “L.Cazzavillan” Arzignano, (Vicenza);
Carmelo Paparo, Patologia Clinica, Ospedale Maggiore Chieri
(Torino); Antonio Insana, SC Patologia Clinica, Ospedale Santa
Croce Moncalieri, Moncalieri (Torino); Serena Rupoli, Clinica
Ematologica, AOU-Ospedali Riuniti Ancona, Ancona; Giuseppe
Malcangi, Centro Emofilia e Trombosi, Policlinico di Bari, Bari;
Maddalena Loredana Zighetti, SIMT-AO San Paolo, Milano;
Catello Mangione, Sezione Trasfusionale Ospedale di Galatina,
Galatina (Lecce); Domenico Lione, UOC Patologia Clinica,
Ospedale Perrino, Brindisi; Paola Casasco, Servizio Medicina
Trasfusionale Tortona (Alessandria); Giovanni Nante, UOS
Geriatria ULSS 16 Padova, Padova; Alberto Tosetto, Divisione
di Ematologia, Ospedale San Bortolo, Vicenza; Vincenzo Oriana,
Centro Emofilia, Presidio Ospedaliero Morelli-Reggio Calabria;
Nicola Lucio Liberato, UO Medicina Interna Ospedale di
Casorate Primo, Pavia.
Disclosures
None.
References
1. Fountain EM, Arepally GM. Etiology and complications of thrombocytopenia in
hospitalized medical patients. J Thromb Thrombolysis. 2017;43:429–436.
2. Bonaccio M, Di Castelnuovo A, Costanzo S, De Curtis A, Donati MB, Cerletti C,
de Gaetano G, Iacoviello L, Moli-sani I. Age- and sex-based ranges of platelet
count and cause-specific mortality risk in an adult general population:
prospective findings from the Moli-sani study. Platelets. 2018;29:312–315.
3. Leader A, Ten Cate H, Spectre G, Beckers EAM, Falanga A. Antithrombotic
medication in cancer-associated thrombocytopenia: current evidence and
knowledge gaps. Crit Rev Oncol Hematol. 2018;132:76–88.
4. Yadav M, Genereux P, Giustino G, Madhavan MV, Brener SJ, Mintz G, Caixeta A,
Xu K, Mehran R, Stone GW. Effect of baseline thrombocytopenia on ischemic
outcomes in patients with acute coronary syndromes who undergo percuta-
neous coronary intervention. Can J Cardiol. 2016;32:226–233.
5. Park J, Cha MJ, Choi YJ, Lee E, Moon I, Kwak S, Kwon S, Yang S, Lee S, Choi EK,
Oh S. Prognostic efficacy of platelet count in patients with nonvalvular atrial
fibrillation. Heart Rhythm. 2019;16:197–203.
6. Suarez FERNANDEZ C, Formiga F, Camafort M, Cepeda Rodrigo M, Diez-Manglano
J, Pose REINO A, Tiberio G, Mostaza JM; Grupo de trabajo de Riesgo vascular de
la SEMI. Antithrombotic treatment in elderly patients with atrial fibrillation: a
practical approach. BMC Cardiovasc Disord. 2015;15:143.
7. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ,
Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW,
Wallentin L; ARISTOTLE Investigators. Apixaban for reduction in stroke and
other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and
rationale. Am Heart J. 2010;159:331–339.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J,
Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R,
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering
Committee and Investigators. Dabigatran versus warfarin in patients with atrial
fibrillation. N Engl J Med. 2009;361:1139–1151.
9. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M,
Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the
novel factor Xa inhibitor edoxaban compared with warfarin in patients with
atrial fibrillation: design and rationale for the Effective aNticoaGulation with
factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial
Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635–641.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G,
Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz
DOI: 10.1161/JAHA.119.012596 Journal of the American Heart Association 8
Thrombocytopenia and Atrial Fibrillation Pastori et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin
in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
11. Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F,
Palareti G; START-Register. The Italian START-Register on anticoagulation with
focus on atrial fibrillation. PLoS One. 2015;10:e0124719.
12. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American
Society of Hematology. The American Society of Hematology 2011 evidence-
based practice guideline for immune thrombocytopenia. Blood.
2011;117:4190–4207.
13. Lu L, Zhan Y, Yu J, Sui L. Prevalence of thrombocytopenia and its association
with serum magnesium. Biol Trace Elem Res. 2016;169:46–51.
14. Violi F, Loffredo L, Carnevale R, Pignatelli P, Pastori D. Atherothrombosis and
oxidative stress: mechanisms and management in elderly. Antioxid Redox
Signal. 2017;27:1083–1124.
15. Lambert MP. Platelets in liver and renal disease. Hematology Am Soc Hematol
Educ Program. 2016;2016:251–255.
16. Santimone I, Di Castelnuovo A, De Curtis A, Spinelli M, Cugino D, Gianfagna F,
Zito F, Donati MB, Cerletti C, de Gaetano G, Iacoviello L; MOLI-SANI Project
Investigators. White blood cell count, sex and age are major determinants of
heterogeneity of platelet indices in an adult general population: results from
the MOLI-SANI project. Haematologica. 2011;96:1180–1188.
17. Bjorck F, Renlund H, Lip GY, Wester P, Svensson PJ, Sjalander A. Outcomes in
a warfarin-treated population with atrial fibrillation. JAMA Cardiol. 2016;1:172–
180.
18. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M,
Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY
Investigators. Causes of death and influencing factors in patients with
atrial fibrillation: a competing-risk analysis from the randomized evaluation
of long-term anticoagulant therapy study. Circulation. 2013;128:2192–
2201.
19. Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-
Gea ML, Vargas-Castrillon E. Causes of death in anticoagulated patients with
atrial fibrillation. J Am Coll Cardiol. 2016;68:2508–2521.
20. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D,
Ivanes F, Babuty D, Lip GY. Causes of death and influencing factors in patients
with atrial fibrillation. Am J Med. 2016;129:1278–1287.
21. Monch S, Boeckh-Behrens T, Kreiser K, Blum P, Hedderich D, Maegerlein C,
Berndt M, Lehm M, Wunderlich S, Zimmer C, Friedrich B. Thrombocytopenia
and declines in platelet counts: predictors of mortality and outcome after
mechanical thrombectomy. J Neurol. 2019;266:1588–1595.
22. Rubinfeld GD, Smilowitz NR, Berger JS, Newman JD. Association of thrombo-
cytopenia, revascularization, and in-hospital outcomes in patients with acute
myocardial infarction. Am J Med. 2019;132:942–948.e5.
23. Ito S, Watanabe H, Morimoto T, Yoshikawa Y, Shiomi H, Shizuta S, Ono K,
Yamaji K, Soga Y, Hyodo M, Shirai S, Ando K, Horiuchi H, Kimura T. Impact of
baseline thrombocytopenia on bleeding and mortality after percutaneous
coronary intervention. Am J Cardiol. 2018;121:1304–1314.
24. Pastori D, Pignatelli P, Farcomeni A, Nocella C, Bartimoccia S, Carnevale R,
Violi F. Age-related increase of thromboxane b2 and risk of cardiovascular
disease in atrial fibrillation. Oncotarget. 2016;7:39143–39147.
25. Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S,
Nocella C, Vicario T, Bucci T, Carnevale R, Lip GY, Violi F. Urinary 11-dehydro-
thromboxane B2 is associated with cardiovascular events and mortality in
patients with atrial fibrillation. Am Heart J. 2015;170:490–497.e491.
26. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for
maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane
Database Syst Rev. 2015:CD005049.
27. Sullivan SD, Orme ME, Morais E, Mitchell SA. Interventions for the treatment
of atrial fibrillation: a systematic literature review and meta-analysis. Int J
Cardiol. 2013;165:229–236.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.119.012596 Journal of the American Heart Association 9
Thrombocytopenia and Atrial Fibrillation Pastori et al
